[A16-50] Ramucirumab (colorectal cancer) - Addendum to Commission A16-10
Last updated 01.09.2016
Commission awarded on 15.07.2016 by the Federal Joint Committee (G-BA).
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
|A19-73||Ramucirumab (hepatocellular carcinoma) - Benefit assessment according to §35a Social Code Book V||Commission completed|
|A16-10||Ramucirumab (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V||Commission completed|